(0)

ViroCyt

ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.

Recent News

up
down
  • ViroCyt® Continues to Innovate for the Gene Therapy Field

    BROOMFIELD, CO–(Marketwired – May 4, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today the release of new member of the ViroTag® portfolio of antibody-based detection reagents: ViroTag AAV5. Adeno-Associated Virus, or AAV, is a family of 12 different serotypes, and are a major tool in the gene therapy field, with well over 100  Continue Reading »

    Read More arrow
  • ViroCyt® Announces a Paradigm Shift in Influenza Virus Quantification: ViroTag® INVX

    BROOMFIELD, CO–(Marketwired – March 24, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today that it has developed and launched an antibody-based detection system for influenza capable of determining virus titer for both flu A and flu B during a one minute analysis. Every year, the flu virus causes millions of cases of illness  Continue Reading »

    Read More arrow
  • ViroCyt Releases ViroTag AAV2-3: Rapid and Direct Quantification of Gene Therapy Viral Vectors

    BOULDER, CO–(Marketwire – January 19, 2016) – ViroCyt, the leader in rapid virus quantification, announced today the release of the most recent addition to its ViroTag portfolio: ViroTag AAV2-3.  When combined with the Virus Counter 3100, this reagent enables real-time quantification of Adeno-associated virus serotypes 2 and 3, both of which are currently being developed as  Continue Reading »

    Read More arrow
  • ViroCyt Launches ViroTag for Direct, Real-Time, Antibody-Based Virus Quantification

    BOULDER, CO–(Marketwire – September 29, 2015) – ViroCyt, the leader in rapid virus quantification, announced today the introduction of a new paradigm in virus quantification building upon its award winning Virus Counter technology.  The importance of viruses as both a health threat and as a tool for addressing a growing list of diseases continues to increase  Continue Reading »

    Read More arrow
  • ViroCyt Appoints Greg Krueger to Lead Global Sales

    BOULDER, CO–(Marketwired – July 28, 2015) – ViroCyt, the leader in rapid virus quantification, announced today that Greg Krueger has joined the team as Vice President of Global Sales. Greg brings over 20 years of experience in the commercialization of life science products, including sales, marketing and business development roles at Sartorius Stedim Biotech, Becton Dickinson,  Continue Reading »

    Read More arrow

Upcoming Events


Aug
15

Bioprocessing Summit (Boston, Massachusetts) Event Details

Oct
4

BioProcess International Conference & Exposition (Boston, Massachusetts) Event Details

Oct
10

World Vaccine Congress (Barcelona, Spain) Event Details